IRADIMED (IRMD) is back in focus after reporting double digit revenue and earnings growth for Q1 2026, reaffirming full year guidance and declaring a regular cash dividend alongside its next generation 3870 MRI infusion pump rollout.

IRADIMED shares have pulled back recently, with a 30 day share price return of a 10.78% decline and a 90 day share price return of an 8.51% decline, even though the 1 year total shareholder return is 70.78% and the 5 year total shareholder return is 231.02%. This suggests longer term holders have still seen strong compounding, while short term momentum has cooled around the recent earnings, guidance and dividend news.

If strong execution in MRI compatible equipment has your attention, it can be useful to see what else is gaining traction in healthcare focused AI. Take a look at 35 healthcare AI stocks

With IRADIMED trading below the average analyst price target yet screening as significantly overvalued on some intrinsic measures, are you looking at a rare pullback in a quality compounder, or at a stock where the market already prices in future growth?

Most Popular Narrative: 28% Undervalued

IRADIMED's most followed valuation narrative pegs fair value at $118.67 against a last close of $85.86, framing the recent pullback as a gap between price and expectations.

The introduction and FDA approval of the new 3870 MRI-compatible IV pump, with significantly enhanced usability and technology over the legacy product, is expected to catalyze a major replacement cycle among hospitals and imaging centers, unlocking large-scale, recurring device and consumable revenues. This supports a step change in revenue growth as existing customers upgrade and potential new customers previously deterred by usability issues are attracted.

Curious what kind of revenue runway and margin profile could justify that higher fair value and premium P/E setup? The narrative leans on a detailed path for growth, profitability and capital returns that goes well beyond a simple price target headline.

Result: Fair Value of $118.67 (UNDERVALUED)

However, you still need to weigh concentration in MRI compatible pumps and monitors, as well as any slowdown in hospital capital spending, which could challenge this upbeat setup.

Another Angle On Valuation

While the popular narrative treats IRADIMED as 28% undervalued at $118.67 fair value, the earnings multiple paints a tougher picture. The current P/E of 46.5x sits almost double the estimated fair ratio of 19.6x and is also high versus the US Medical Equipment industry at 23.6x and peers at 54.5x. That combination suggests a lot of success is already priced in, so the key question is whether you are comfortable paying a higher price for this earnings profile.

Next Steps

With sentiment clearly mixed, do you want to move fast and test these views against the underlying data yourself? Start by weighing the company's 3 key rewards

Looking for more investment ideas?

Do not stop with a single stock when there are plenty of other opportunities you can quickly sort through using the Simply Wall Street Screener.

• Target potential bargains by scanning companies that combine quality fundamentals with attractive pricing through the 51 high quality undervalued stocks.
• Boost your income focus by lining up stocks that offer higher yields and resilience using the 13 dividend fortresses.
• Sleep easier by zeroing in on businesses that carry lower risk scores and stronger balance sheets with the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.